Position in SEPN
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$168,110,467
-$26,934,054 QoQ
Shares Held
6,995,858
0.0% QoQ
Ownership
15.5%
of shares outstanding
% of Portfolio
1.78%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2024
6 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in SEPN Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026RA CAPITAL MANAGEMENT, L.P. holds $9,134,713,488 across 74 Biotechnology names. SEPN ranks #13 (1.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ASND |
Ascendis Pharma A/S
|
10,281,496 | $2,351,686,580 | |
| 2 | PCVX |
Vaxcyte, Inc.
|
11,474,599 | $666,788,947 | |
| 3 | RYTM |
Rhythm Pharmaceuticals, Inc.
|
6,666,837 | $579,814,813 | |
| 4 | TYRA |
Tyra Biosciences, Inc.
|
12,198,625 | $467,207,337 | |
| 5 | SION |
Sionna Therapeutics, Inc.
|
9,905,045 | $397,093,254 | |
| 6 | EWTX |
Edgewise Therapeutics, Inc.
|
10,428,437 | $328,495,765 | |
| 7 | NAMS |
NewAmsterdam Pharma Co N.V.
|
9,550,191 | $305,701,613 | |
| 8 | NUVL |
Nuvalent, Inc.
|
2,534,145 | $259,623,155 |
All Filings in SEPN
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $168,110,467 | 6,995,858 | Shares | Sole | 2026-05-15 | |
| 2025-12-31 | $195,044,521 | 6,995,858 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $131,592,088 | 6,995,858 | Shares | Sole | 2025-11-14 | |
| 2025-06-30 | $73,946,219 | 6,995,858 | Shares | Sole | 2025-08-14 | |
| 2025-03-31 | $40,506,017 | 6,995,858 | Shares | Sole | 2025-05-15 | |
| 2024-12-31 | $160,205,148 | 6,995,858 | Shares | Sole | 2025-02-14 | |
| No filing history on record for this holder in this stock. | ||||||